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vrevention of thromboembolism is a principal aim of atrial
brillation management. Although the mechanisms under-
ying thrombogenesis in atrial fibrillation are clearly com-
lex and remain only partly understood, it is intuitive that
estoration and reliable maintenance of sinus rhythm is
robably the best preventive strategy against thromboem-
olism. Over the past decade, catheter ablation has emerged as
potential cure for atrial fibrillation. Many centers worldwide
ave been reporting relatively high success rates with few
ssociated complications after ablation of atrial fibrillation
n selected patient populations. Particularly with increasing
se of this therapy has come an obvious need finally to
nswer one of the most important questions related to this
herapy, namely does long-term maintenance of sinus
hythm after successful catheter ablation eliminate stroke
isk in patients with atrial fibrillation, thereby permitting
iscontinuation of oral anticoagulation therapy (OAT)?
See page 735
nfortunately, few data exist to guide us in this area. The
anagement of OAT in patients who have undergone atrial
brillation ablation has largely been left to the individual
udgment of the treating physician. However, several prac-
ice patterns have emerged based on the apparent presence
r absence of atrial fibrillation, duration of recurrent epi-
odes, and stroke risk stratification, the CHADS2 (conges-
ive heart failure, hypertension, age 75 years, diabetes
ellitus, and prior stroke or transient ischemic attack)
cheme being the most commonly used (1,2).
In this issue of the Journal, Themistoclakis et al. (3)
resent the largest and the only multicenter experience to
ate addressing this issue. The records of 3,355 patients
rom 5 well-known atrial fibrillation ablation centers were
tudied. In 2,692 patients, OAT was discontinued 3 to 6
onths after ablation, although these patients were contin-
ed on aspirin (Off-OAT group). The decision was made
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
From the Case Western Reserve University/University Hospitals Case Medical
enter, Cleveland, Ohio. Supported in part by the Jennie Zoline, Blue Dot, anda
lenstone Foundations. Dr. Waldo is a consultant for Boehringer-Ingelheim Phar-
aceuticals and Ortho-McNeil-Janssen Pharmaceuticals.n an individual-case basis according to the local institu-
ional policy regardless of the CHADS2 score, but we note
hat 347 patients had a CHADS2 score 2. As a general
ule, warfarin was discontinued if the patient did not
xperience any recurrence of atrial tachyarrhythmia, did not
ave severe pulmonary vein stenosis, and did not have severe
eft atrial mechanical dysfunction. The rest of the patients
n  663) remained on oral anticoagulation treatment after
he 3- to 6-month period post-ablation (On-OAT group).
fter an average follow-up of 28  13 months, only 2
0.07%) patients had experienced an ischemic stroke in the
ff-OAT group, and no patient with a CHADS2 score 2
ad experienced a stroke. In the On-OAT group, after an
verage follow-up period of 24 15 months, only 3 (0.45%)
atients had experienced an ischemic stroke. One of the 3
atients experienced this event after a cardioversion. The
ther 2 patients had unsuccessful ablations, with 1 of them
aving a subtherapeutic international normalized ratio dur-
ng the neurological event. On the basis of these results, the
uthors concluded that “ . . . it seems that the risk–benefit
atio favors the discontinuation of OAT after successful AF
blation even in patients at moderate-high risk of TE based
n CHADS2 score alone” (3). They also concluded that “. . .
his conclusion needs to be confirmed by future large
andomized trials” (3). After a careful read of the paper by
hemistoclakis et al. (3), we strongly support the latter
onclusion, but believe equally strongly that it is premature
o accept the former conclusion.
What should we do about OAT in patients who seem-
ngly have had a successful cure of their atrial fibrillation?
he desire, of course, is to be able safely to terminate OAT
n patients who, because of the presence of stroke risk
actors, especially those with a CHADS2 score 2, would
therwise be well advised to continue OAT (4–6). If there
s no longer any risk in these patients because they are cured
f atrial fibrillation, clearly the expectation is that there
hould be no need for OAT. However, before that expec-
ation can be realized, there are several important questions
hat need to be addressed and answered. How can we be
ure that a patient is cured? The authors certainly tried to be
ure, but there are important concerns regarding their
vailable data. Follow-up was often not face-to-face, in-
olved long intervals between each follow-up visit, and on
verage was only a little over 2 years. The latter is especially
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February 23, 2010:744–6 Do Not Stop the Warfarin Until . . .orrisome in patients with stroke risks in light of recent
tudies that have shown that even after there has been no
pparent atrial fibrillation recurrence for 1 year, there is a 5%
o 13% recurrence in year 2, and an actuarial recurrence rate
f 25% to 46.8% in 5 years and 54.6% at 6 years (7–10).
hus, how can one be sure that in patients at high risk for
troke (CHADS2 score 2), it is safe to stop OAT?
oreover, there were only 347 of the latter patients in this
tudy, of the 3,355 total patients. In fact, the great majority
f patients in this study (82%) would not necessarily have
arranted OAT post-ablation of atrial fibrillation because
heir CHADS2 score was 1 (4–6).
Additionally, there is the issue of how much atrial
brillation is a clinically meaningful recurrence, potentially
arranting OAT (at least with a CHADS2 score 2).
tudies have shown that there is as much as a 7-fold increase
n asymptomatic atrial fibrillation after radiofrequency ab-
ation of atrial fibrillation (11). Perhaps the best illustration
f the relevance of such data comes from Martinek et al.
12), who reported on patients who had had radiofrequency
blation of atrial fibrillation, but also happened to have an
T-500 full-disclosure implantable pacemaker device
Medtronic, Inc., Minneapolis, Minnesota) in place. In this
mall series (n  14), 4 patients had a symptomatic
ecurrence (a 71% success rate), but using a 24- to 48-h
olter monitor every 6 months, they found another recur-
ence, decreasing the success rate to 64%. Then using a
-week Holter monitor every 6 months, they found yet
nother case, reducing the success rate to 58%, and then
ith the continuous monitoring of the AT-500, they found
other recurrences, reducing the success rate to 43%. It
eems the more rigorous the monitoring, the more atrial
brillation is uncovered. Then, of course, there is the need
o know how much atrial fibrillation recurrence warrants
AT. And all this should be considered in light of the
HADS2 score. Furthermore, we know that a recurrence of
hort duration one time does not indicate that the duration
f recurrence will always be short. Thus, as the authors
ecognized, in the presence of stroke risk factors, how long
ust an episode or episodes of atrial fibrillation last to
mpact the likelihood of subsequent stroke, and therefore, to
dentify the need for prophylactic OAT? They use a
uration of 1 min.
Additionally, that there were strikingly few strokes in
his study is of considerable interest. It may be, or
robably is, explained by one or more of the following: 1)
he great majority (82%) of patients had a CHADS2
core of 1, that is, they had a very low stroke risk to
egin with (13), and the guidelines consensus would not
ave mandated OAT in any event (4 – 6); 2) the
ollow-up surveillance was really superb (perhaps espe-
ially because patients taking their pulse daily really
orked), such that they picked up clinically meaningful
trial fibrillation recurrences quickly and restarted OAT
77 patients were restarted on OAT); 3) in patients with
troke risks, the follow-up was simply not good enough toick up all of the atrial fibrillation recurrences; and
) strokes were simply missed.
We have already remarked that the authors observed a
ery low incidence of thromboembolism in the Off-OAT
roup. However, also curious is that the incidence of stroke
as strikingly low in the On-OAT group. Warfarin reduces
ut does not eliminate the risk of stroke in patients with
trial fibrillation. Even in the patients with a CHADS2
core of 0, the expected annual incidence of stroke should be
ignificantly higher than the overall incidence of 0.23% that
he authors reported in their patient population (14–16).
owever, their reported incidence of major hemorrhagic
pisodes in the OAT group matches the incidence reported
n the literature (14,15). Paradoxically, because of the very
ow stroke rates observed in this study, it appears that the
AT group, in which 72% of the patients had experienced
rrhythmic recurrences, 39% of the patients had CHADS2
cores of 1, and 37% had CHADS2 scores of 2, would
ave been better served with aspirin rather than with
arfarin therapy (6). The authors themselves remind us that
patients with a thromboembolic risk of 2% per year or less
o not benefit substantially from OAT, and according to
he international guidelines, should not be treated with this
herapy” (3). One explanation for such a low incidence of
troke may be that the arrhythmic recurrences in the OAT
roup were brief in duration and/or clinically not significant.
evertheless, the surprising and discrepant paucity of
hromboembolic events across the groups in this retrospec-
ive study seriously limits deriving a meaningful conclusion
egarding discontinuation of warfarin therapy post-ablation,
specially in patients with higher risk factors for stroke.
Secondly, only 347 (13%) of the patients in the Off-OAT
roup had a CHADS2 score 2, and only 10 patients had
CHADS2 score of 5 to 6. Current guidelines suggest
arfarin therapy in patients with atrial fibrillation and
HADS2 scores of 2 (4–6). To change this practice on
he basis of data from such a small subgroup in a nonran-
omized, observational study seems unwise, and is not
ecommended by the consensus statements (4,6). Again, the
eed for prospective studies is clear and much needed.
It would also help to understand the mechanism of atrial
brillation in the same way we understand the mechanism
f atrial flutter, atrioventricular re-entrant tachycardia, and
trioventricular nodal re-entry tachycardia. Catheter abla-
ion of these well-understood arrhythmias approaches a
00% acute success rate, and has an insignificant recurrence
ate even after a very long follow-up period. Until then, the
eart Rhythm Society/European Heart Rhythm Associa-
ion/European Cardiac Arrhythmia Society atrial fibrilla-
ion ablation consensus statement recommendations should
robably be followed (4):
. Warfarin is recommended for all patients for at least 2
months after an AF ablation procedure.
. Decisions regarding the use of warfarin more than 2
months after ablation should be based on the patient’s
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of AF.
. Discontinuation of warfarin therapy post-ablation is
generally not recommended in patients who have a
CHADS2 score 2.
In short, although this is clearly the largest follow-up of
ost-atrial fibrillation ablation patients and late stroke, it is
eally only hypothesis generating. These data cry out for a
rospective, randomized clinical trial that includes stan-
ardized methods of follow-up to assess and characterize
ecurrence of atrial fibrillation and to determine the inci-
ence/prevalence of stroke.
Therefore, our conclusion: do not stop the warfarin until
e have prospective, randomized clinical trials that can help
uide us in providing anticoagulation therapy for our
atients.
eprint requests and correspondence: Dr. Ivan Cakulev, Divi-
ion of Cardiovascular Medicine, University Hospitals Case Med-
cal Center, 11100 Euclid Avenue, MS LKS 5038, Cleveland,
hio 44106-5038. E-mail: Ivan.Cakulev@case.edu.
EFERENCES
1. Meiltz A, Zimmermann M, Urban P, Bloch A. Atrial fibrillation
management by practice cardiologists: a prospective survey on the
adherence to guidelines in the real world. Europace 2008;10:674–80.
2. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW,
Radford MJ. Validation of clinical classification schemes for predicting
stroke: results from the National Registry of Atrial Fibrillation. JAMA
2001;285:2864–70.
3. Themistoclakis S, Corrado A, Marchlinski FE, et al. The risk of
thromboembolism and need for oral anticoagulation after successful
atrial fibrillation ablation. J Am Coll Cardiol 2010;55:735–43.
4. Calkins H, Brugada J, Packer DL, et al. HRS/EHRA/ECAS expert
consensus statement on catheter and surgical ablation of atrial fibril-
lation: recommendations for personnel, policy, procedures and follow-
up. A report of the Heart Rhythm Society (HRS) Task Force on
Catheter and Surgical Ablation of Atrial Fibrillation. Heart Rhythm
2007;4:816–61. K5. Natale A, Raviele A, Arentz T, et al. Venice chart international
consensus document on atrial fibrillation ablation. J Cardiovasc Elec-
trophysiol 2007;18:560–80.
6. Fuster V, Ryden LE, Cannom DS, et al. ACC/AHA/ESC 2006
guidelines for the management of patients with atrial fibrillation—
executive summary: a report of the American College of Cardiology/
American Heart Association Task Force on Practice Guidelines and
the European Society of Cardiology Committee for Practice Guide-
lines (Writing Committee to Revise the 2001 Guidelines for the
Management of Patients With Atrial Fibrillation). J Am Coll Cardiol
2006;48:854–906.
7. Pappone C, Rosanio S, Augello G, et al. Mortality, morbidity, and
quality of life after circumferential pulmonary vein ablation for atrial
fibrillation: outcomes from a controlled nonrandomized long-term
study. J Am Coll Cardiol 2003;42:185–97.
8. Shah AN, Mittal S, Sichrovsky TC, et al. Long-term outcome
following successful pulmonary vein isolation: pattern and prediction
of very late recurrence. J Cardiovasc Electrophysiol 2008;19:661–7.
9. Bertaglia E, Tondo C, De Simone A, et al. Does catheter ablation cure
atrial fibrillation? Single-procedure outcome of drug-refractory atrial
fibrillation ablation: a 6-year multicentre experience. Europace 2009
Nov 3 [E-pub ahead of print].
0. Sawhney N, Anousheh R, Chen WC, Narayan S, Feld GK. Five-year
outcomes after segmental pulmonary vein isolation for paroxysmal
atrial fibrillation. Am J Cardiol 2009;104:366–72.
1. Hindricks G, Piorkowski C, Tanner H, et al. Perception of atrial
fibrillation before and after radiofrequency catheter ablation: relevance
of asymptomatic arrhythmia recurrence. Circulation 2005;112:307–13.
2. Martinek M, Aichinger J, Nesser HJ, Ziegler PD, Purerfellner H.
New insights into long-term follow-up of atrial fibrillation ablation:
full disclosure by an implantable pacemaker device. J Cardiovasc
Electrophysiol 2007;18:818–23.
3. Gage BF, van Walraven C, Pearce L, et al. Selecting patients with
atrial fibrillation for anticoagulation: stroke risk stratification in pa-
tients taking aspirin. Circulation 2004;110:2287–92.
4. Go AS, Hylek EM, Chang Y, et al. Anticoagulation therapy for stroke
prevention in atrial fibrillation: how well do randomized trials translate
into clinical practice? JAMA 2003;290:2685–92.
5. Singer DE, Chang Y, Fang MC, et al. The net clinical benefit of
warfarin anticoagulation in atrial fibrillation. Ann Intern Med 2009;
151:297–305.
6. Halperin JL. Ximelagatran compared with warfarin for prevention of
thromboembolism in patients with nonvalvular atrial fibrillation:
rationale, objectives, and design of a pair of clinical studies and baseline
patient characteristics (SPORTIF III and V). Am Heart J 2003;146:
431–8.ey Words: atrial fibrillation y oral anticoagulation y catheter ablation.
